Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate

Much of the Most-Favoured-Nation debate asks whether the United States can persuade other countries to pay more for medicines. Germany is the market where that question is hardest to answer and where it matters most.

Discussion of Most-Favoured-Nation (MFN) drug pricing has converged on a single question: can the United States persuade other wealthy countries to pay more for medicines, and so shoulder a larger share of the cost of pharmaceutical innovation?

View More